Federation Des Caisses Desjardins Du Quebec Phathom Pharmaceuticals, Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Aug 14, 2024	SELL	$6.46 - $12.11 $3,876 - $7,266	-600 Closed	0 $0
Q2 2022 Aug 14, 2024	BUY	$6.2 - $15.5 $3,720 - $9,300	600 New	600 $5.06 Million

Others Institutions Holding PHAT

# of Institutions

144

Shares Held

73.6M

Call Options Held

42.3K

Put Options Held

45.7K

Frazier Life Sciences Management, L.P. Menlo Park, CA

10.1M
Shares

$75.8 Million
9.84% of portfolio
Medicxi Ventures Management (Jersey) LTD

7.46M
Shares

$56 Million
28.04% of portfolio
Jennison Associates LLC

5.87M
Shares

$44 Million
0.07% of portfolio
Invesco Ltd. Atlanta, GA

4.1M
Shares

$30.7 Million
0.01% of portfolio
Carlyle Group Inc. Washington, DC

3.5M
Shares

$26.2 Million
9.52% of portfolio

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $294M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account